SPX-101 / SparX, KPC Pharma - LARVOL DELTA

Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: SparX Biotech(Jiangsu) Co., Ltd. | N=27 ➔ 0 | Trial completion date: Aug 2023 ➔ Aug 2024 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Mar 2023 ➔ Apr 2024

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial withdrawal • Oncology • Solid Tumor • CD4

The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy (PRNewswire) - "Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance with Arovella Therapeutics Ltd (ASX: ALA). This collaboration emphasizes the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-iNKT cell therapy."

Licensing / partnership • Solid Tumor

Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: SparX Biotech(Jiangsu) Co., Ltd.

New P1 trial • Oncology • Solid Tumor